Writedowns and US decline hit Dr Reddy's third quarter
This article was originally published in Scrip
Executive Summary
Dr Reddy’s Laboratories reported a loss of Rs5.2 billion ($112 million) for the third quarter ended December 31st, 2009, hit by writedowns in its German business, Betapharm, and a decline in revenues from the US. Total revenues for the period fell by 6% to Rs17.3 billion.
You may also be interested in...
USV Primes German Base With Juta Acquisition
USV is building on its play in Europe with the acquisition of Juta Pharma in Germany – a market that has been fostering generics alongside supporting innovative medicines.
USV Primes German Base With Juta Acquisition
USV is building on its play in Europe with the acquisition of Juta Pharma in Germany – a market that has been fostering generics alongside supporting innovative medicines.
India IPR Realities: Pharma, Legal Heads Discuss Winds Of Change, ‘Damocles Sword’
Leaders from Novartis, Bayer, Sun Pharma, the Indian Pharmaceutical Alliance, Médecins Sans Frontières and Anand and Anand discuss India’s evolving intellectual property rights landscape, including pre-grant oppositions, enforcement action and other realities. Concerns around evergreening, restrictions on patent-eligible subject matter and compulsory licensing were also key talking points at a recent conference in Hyderabad.